Abstract
Germ-cell testicular cancer is a highly curable disease, with a 5-year survival > 90%. For instance, among patients diagnosed in the beginning of the 2000s, mean survival was 97% in Europe and 95% in the United States (Verdecchia et al. 2007). It improved dramatically when cisplatinum-based chemotherapy regimens were introduced at the end of the 1970s (Einhorn and Donohue 1977). As a consequence of the improvements in treatment, a secular rise in incidence of testicular cancer, which constantly doubled every 20 years, is nowadays associated in most developed countries with the lowest mortality rate in the last 50 years (Bray et al. 2006) (Figure 16.1). Therefore, the prevalence of survivors from testicular cancer has been increasing with time with a parallel increasing concern on the long-term health consequences of the disease and the treatments. These include mainly infertility, long-term cardio-vascular effects, and increased incidence of second primary cancers.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bokemeyer, C., Schmoll, H.J., Kuczyk, M.A., Beyer, J., and Siegert, W. (1995) Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer. J. Natl. Cancer Inst. 87:58–60
Bray, F., Richiardi, L., Ekbom, A., Pukkala, E., Cuninkova, M., and Moller, H. (2006) Trends in testicular cancer incidence. and mortality in. 22 European countries: continuing increases in incidence. and declines in. mortality. Int. J. Cancer 118:3099–3111
Breslow, N.E., and Day, N.E. (1987) Statistical methods in cancer research. Volume II – The design. and analysis of. cohort studies. IARC. Sci. Publ. 82:96–98
Curtis, R.E., and Ries LAG. (2006) Methods. In: Curtis, R.E., Freedman, D.M., Ron, E., Ries LAG., Hacker, D.G., Edwards, B.K., Tucker, M.A., Fraumeni JFJ (eds) New malignancies among cancer survivors: SEER Cancer Registries., 1973-2000, vol NIH Publ. No. 05-5302 Bethesda, National Cancer Institute
Einhorn, L.H., and Donohue, J. (1977) Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann. Intern. Med. 87:293–298
Gooley, T.A., Leisenring, W., Crowley, J., and Storer, B.E. (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat. Med. 18:695–706
IARC (2000) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Some Antiviral and Antineoplastic Drugs, and Other Pharmaceutical Agents. International Agency for Research on cancer, Lyon
Kaldor, J.M., Day, N.E., Band, P., Choi, N.W., Clarke, E.A., Coleman, M.P., Hakama, M., Koch, M., Langmark, F., Neal, F.E., Pettersson, F., Pompe-Kirn, V., Prior, P., and Storm, H.H. (1987) Second malignancies following testicular cancer., ovarian cancer and Hodgkin’s disease: an international collaborative study among cancer registries. Int. J. Cancer 39:571–585
Kim HT (2007) Cumulative incidence in competing risks data. and competing risks. regression analysis. Clin. Cancer. Res. 13:559–565
Kollmannsberger, C., Hartmann, J.T., Kanz, L., and Bokemeyer, C. (1999) Therapy-related malignancies following treatment of germ cell cancer. Int. J. Cancer. 83:860–863
Lutke Holzik, M.F., Sijmons, R.H., Sleijfer, D.T., Sonneveld, D.J., Hoekstra-Weebers, J.E., van Echten-Arends, J., and Hoekstra, H.J. (2003) Syndromic aspects of testicular carcinoma. Cancer 97:984–992
Maule, M., Scelo, G., Pastore, G., Brennan, P., Hemminki, K., Tracey, E., Sankila, R., Weiderpass, E., Olsen, J.H., McBride, M.L., Brewster, D.H., Pompe-Kirn, V., Kliewer, E.V., Chia, K.S., Tonita, J.M., Martos, C., Jonasson, J.G., Merletti, F., and Boffetta, P. (2007) Risk of second malignant neoplasms after childhood leukemia and lymphoma: an international study. J. Natl. Cancer. Inst. 99:790–800
Moller, H., Mellemgaard, A., Jacobsen, G.K., Pedersen, D., and Storm, H.H. (1993) Incidence of second primary cancer following testicular cancer. Eur. J. Cancer. 29A:672–676
Muir, C.S., and Percy, C. (1991) Classification and coding for neoplasms. In: Jensen, O.M., Parkin, D.M., MacLennan, R., Muir, C.S., Skeet RG (eds) IARC Scientific Publication No. 95: Cancer registration – principles and methods., vol I Lyon., IARC
Pedersen-Bjergaard, J., Daugaard, G., Hansen, S.W., Philip, P., Larsen, S.O., and Rorth, M. (1991) Increased risk of myelodysplasia. and leukaemia after. etoposide., cisplatin, and bleomycin for germ-cell tumours. Lancet 338:359–363
Preston, D.L., Shimizu, Y., Pierce, D.A., Suyama, A., and Mabuchi, K. (2003) Studies of mortality of atomic bomb survivors. Report 13: Solid cancer. and noncancer disease. mortality: 1950–1997. Radiat. Res. 160:381–407
Richiardi, L., Scelo, G., Boffetta, P., Hemminki, K., Pukkala, E., Olsen, J.H., Weiderpass, E., Tracey, E., Brewster, D.H., McBride, M.L., Kliewer, E.V., Tonita, J.M., Pompe-Kirn, V., Kee-Seng, C., Jonasson, J.G., Martos, C., and Brennan, P. (2007a) Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries. Int. J. Cancer. 120:623–631
Richiardi, L., Pettersson, A., and Akre, O. (2007b) Genetic and environmental risk factors for testicular cancer. Int., J. Androl. 30:230–240; discussion 240–241
Satagopan, J.M., Ben-Porat, L., Berwick, M., Robson, M., Kutler, D., and Auerbach, A.D. (2004) A note on competing risks in survival data analysis. Br. J. Cancer. 91:1229–1235
Scelo, G., Boffetta, P., Hemminki, K., Pukkala, E., Olsen, J.H., Andersen, A., Tracey, E., Brewster, D.H., McBride, M.L., Kliewer, E.V., Tonita, J.M., Pompe-Kirn, V., Chia, K.S., Jonasson, J.G., Martos, C., Colin, D., and Brennan, P. (2006) Associations between small intestine cancer. and other primary. cancers: an international population-based study. Int. J. Cancer. 118:189–196
Schmoll, H.J., Souchon, R., Krege, S., Albers, P., Beyer, J., Kollmannsberger, C., Fossa, S.D., Skakkebaek, N.E., de Wit, R., Fizazi, K., Droz, J.P., Pizzocaro, G., Daugaard, G., de Mulder, P.H., Horwich, A., Oliver, T., Huddart, R., Rosti, G., Paz Ares, L., Pont, O., Hartmann, J.T., Aass, N., Algaba, F., Bamberg, M., Bodrogi, I., Bokemeyer, C., Classen, J., Clemm, S., Culine, S., de Wit, M., Derigs, H.G., Dieckmann, K.P., Flasshove, M., Garcia del Muro, X., Gerl, A., Germa-Lluch, J.R., Hartmann, M., Heidenreich, A., Hoeltl, W., Joffe, J., Jones, W., Kaiser, G., Klepp, O., Kliesch, S., Kisbenedek, L., Koehrmann, K.U., Kuczyk, M., Laguna, M.P., Leiva, O., Loy, V., Mason, M.D., Mead, G.M., Mueller, R.P., Nicolai, N., Oosterhof, G.O., Pottek, T., Rick, O., Schmidberger, H., Sedlmayer, F., Siegert, W., Studer, U., Tjulandin, S., von der Maase, H., Walz, P., Weinknecht, S., Weissbach, L., Winter, E., and Wittekind, C. (2004) European consensus on diagnosis. and treatment of. germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann. Oncol. 15:1377–1399
Surveillance Epidemiology. and End Results. (SEER) Program (www.seer.cancer.gov) (2007) SEER*Stat Database: Mortality – All COD., Public-Use With State., Total, U.S. (1969–2004). National Cancer Institute., DCCPS, Surveillance Research Program., Cancer Statistics Branch.
Travis LB (2006) The epidemiology of second primary cancers. Cancer. Epidemiol. Biomarkers. Prev. 15:2020–2026
Travis, L.B., Curtis, R.E., Storm, H., Hall, P., Holowaty, E., Van Leeuwen, F.E., Kohler, B.A., Pukkala, E., Lynch, C.F., Andersson, M., Bergfeldt, K., Clarke, E.A., Wiklund, T., Stoter, G., Gospodarowicz, M., Sturgeon, J., Fraumeni JF Jr., Boice JD Jr (1997) Risk of second malignant neoplasms among long-term survivors of testicular cancer. J. Natl. Cancer. Inst. 89:1429–1439
Travis, L.B., Andersson, M., Gospodarowicz, M., van Leeuwen, F.E., Bergfeldt, K., Lynch, C.F., Curtis, R.E., Kohler, B.A., Wiklund, T., Storm, H., Holowaty, E., Hall, P., Pukkala, E., Sleijfer, D.T., Clarke, E.A., Boice JD Jr., Stovall, M., and Gilbert, E. (2000) Treatment-associated leukemia following testicular cancer. J. Natl. Cancer. Inst. 92:1165–1171
Travis, L.B., Fossa, S.D., Schonfeld, S.J., McMaster, M.L., Lynch, C.F., Storm, H., Hall, P., Holowaty, E., Andersen, A., Pukkala, E., Andersson, M., Kaijser, M., Gospodarowicz, M., Joensuu, T., Cohen, R.J., Boice JD Jr., Dores, G.M., and Gilbert, E.S. (2005) Second cancers among 40, 576 testicular cancer patients: focus on long-term survivors. J. Natl. Cancer. Inst. 97:1354–1365
van den Belt-Dusebout, A.W., de Wit, R., Gietema, J.A., Horenblas, S., Louwman, M.W., Ribot, J.G., Hoekstra, H.J., Ouwens, G.M., Aleman, B.M., van Leeuwen FE (2007) Treatment-specific risks of second malignancies. and cardiovascular disease. in 5-year survivors of testicular cancer. J. Clin. Oncol. 25:4370–4378
Verdecchia, A., Francisci, S., Brenner, H., Gatta, G., Micheli, A., Mangone, L., and Kunkler, I. (2007) Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data. Lancet. Oncol. 8:784–796
Wanderas, E.H., Fossa, S.D., and Tretli, S. (1997) Risk of a second germ cell cancer after treatment of a primary germ cell cancer in 2201 Norwegian male patients. Eur. J. Cancer. 33:244–252
Weiss, H.A., Darby, S.C., and Doll, R. (1994) Cancer mortality following x-ray treatment for ankylosing spondylitis. Int. J. Cancer. 59:327–338
Williams, S.D., Birch, R., Einhorn, L.H., Irwin, L., Greco, F.A., and Loehrer, P.J. (1987) Treatment of disseminated germ-cell tumors with cisplatin., bleomycin, and either vinblastine or etoposide. N. Engl. J. Med. 316:1435–1440
Woodward M (1999) Epidemiology – study design. and data analysis.. Chapman & Hall, Boca Raton
Yasui, Y., Liu, Y., Neglia, J.P., Friedman, D.L., Bhatia, S., Meadows, A.T., Diller, L.R., Mertens, A.C., Whitton, J., and Robison, L.L. (2003) A methodological issue in the analysis of second-primary cancer incidence in long-term survivors of childhood cancers. Am. J. Epidemiol. 158:1108–1113
Acknowledgments.
We thank Ileana Baldi for useful comments and suggestions. This work was conducted within the framework of projects partially supported by the Compagnia di San Paolo FIRMS, the Italian Association for Cancer Research and the Piedmont Region.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Richiardi, L., Maule, M.M. (2010). Survivors of Germ-Cell Testicular Cancer: Increased Risk of Second Primary Tumors. In: Hayat, M. (eds) Methods of Cancer Diagnosis, Therapy, and Prognosis. Methods of Cancer Diagnosis, Therapy and Prognosis, vol 6. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-2918-8_16
Download citation
DOI: https://doi.org/10.1007/978-90-481-2918-8_16
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-2917-1
Online ISBN: 978-90-481-2918-8
eBook Packages: MedicineMedicine (R0)